07.10.2013 • NewsBiogenBiogen IdecMS treatment

Biogen's New MS Drug Maintains Efficacy Long Term -Study

Biogen Idec's hot-selling new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least four years with no new safety problems, according to interim data from a long-term study. Tecfidera, which analysts expect to eventually dominate the MS market, had sales of $192 million in its first quarter on the market - nearly triple average Wall Street expectations. The Endorse extension study followed patients who had taken part in two pivotal Phase III trials that led to the U.S. approval of Tecfidera.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.